Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV3 | Q8NET8 | 8/20 | 0.39 |
| ▸ | PHGDH | O43175 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.38 |
| ▸ | HTR3A | P46098 | 2/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | GPR6 | P46095 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8034806 | 0.91 | HRH4 (0.38) | TRPV3PHGDHHRH4HTR3AGRM5 | |
| SCHEMBL12872284 | 0.91 | HRH4 (0.38) | TRPV3PHGDHHRH4HTR3AGRM5 | |
| SCHEMBL3046733 | 0.88 | HTR3A (0.36) | TRPV3HRH4HTR3ADRD4CDK1 | |
| SCHEMBL3046737 | 0.88 | HTR3A (0.36) | TRPV3HRH4HTR3ADRD4CDK1 | |
| SCHEMBL12872225 | 0.87 | MAT2A (0.35) | TRPV3HRH4HTR3AGRM5KDM4E | |
| SCHEMBL8033487 | 0.87 | MAT2A (0.35) | TRPV3HRH4HTR3AGRM5KDM4E | |
| SCHEMBL1186844 | 0.86 | TRPV3 (0.34) | TRPV3PHGDHHRH4HTR3A | |
| SCHEMBL8038926 | 0.86 | TRPV3 (0.34) | TRPV3PHGDHHRH4HTR3A | |
| SCHEMBL12872285 | 0.86 | HTR3A (0.34) | TRPV3PHGDHHRH4HTR3ACDK1 | |
| SCHEMBL9275439 | 0.86 | HTR3A (0.34) | TRPV3PHGDHHRH4HTR3ACDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028441-A1 | NOVEL PHENYL-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-03 | — | — | US | disclosed |
| US-20110028441-A1 | NOVEL PHENYL-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028441-A1 | NOVEL PHENYL-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | DPYD, DPM1, DDX41 | TRPV3 277/4885PHGDH 526/4885HRH4 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.